1 / 3
| Product Name | Sodium Hyaluronate |
| Chemical Formula | (C14H20NNaO11)n |
| Chemical Structure |
|
| CAS No. | 9067-32-7 |
| Appearance | White, fine powder |
| Assay | ≥99.5% |
| Solubility | Soluble in water |
| Heavy metals | ≤10ppm |
| Protein | ≤0.1% |
| Bacterial endotoxins | ≤0.5IU/mg |
| Source | Microbial fermentation |
| MOQ | 100 grams |
The rheological characteristics are highly similar to natural human tear mucins. Shear-thinning properties prevent blurred vision during blinking and prolong tear film breakup time when eyes are open.
Optimized for ophthalmic use with endotoxin control stricter than cosmetic-grade raw materials. Non-immunogenic and non-irritating to corneal endothelial cells.
Clinically proven high-purity sodium hyaluronate binds to corneal surface receptors, promoting corneal epithelial cell migration, healing, and hydration.
Produced in GMP-certified lines with enterprise standards (MSDS) and COA test reports, fully supporting global pharmaceutical and medical device registration.
High-density deep liquid fermentation using selected non-GMO streptococci, with strict control over temperature, pH, and dissolved oxygen to ensure high molecular weight hyaluronic acid secretion.
Multi-stage precision filtration and high-pressure sterilization thoroughly eliminate producing bacteria, yielding a clear coarse filtrate.
Advanced ultrafiltration and adsorption technologies selectively remove nucleic acids, proteins, and bacterial endotoxins to meet strict ophthalmic standards.
Gradient precipitation with pharmaceutical-grade ethanol crystallizes the sodium hyaluronate, improving product purity and desalination.
Low-temperature vacuum drying in a sterile Class 100 clean area prevents molecular weight degradation and controls weight loss during drying.
Uniform fine powder processing via airflow milling and aseptic double-sealing. Release requires passing testing (including HPLC) with a Certificate of Analysis (COA) issued.
